700 liver transplant patients studied to uncover hidden clot risks
NCT ID NCT06513780
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This observational study follows 700 adult liver transplant recipients to understand how portal vein thrombosis (a blood clot in the liver's main vein) impacts their recovery and long-term health. Researchers will compare those with and without the clot to identify risk factors and build a prediction tool. No treatment or intervention is given—this is purely to gather knowledge.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better predict and manage complications like portal vein thrombosis after liver transplant, improving patient care.
- What could go wrong
- This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all transplant patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 700 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2016
- Expected to finish
-
Dec 2025
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who underwent in situ liver transplantation at the Liver Transplantation Center of Beijing Friendship Hospital affiliated with Capital Medical University from 2016-1-1 to 2025-12-31
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Liver transplantation recipients 2. Aged 18 years or older. Exclusion Criteria: 1. Retransplantation 2. Multi-organ transplantation 3. Portal vein tumor thrombus
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Portal vein thrombosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New blood thinner trial aims to prevent rebleeding in liver patients
- Computer model helps cirrhosis patients get blood thinner doses right faster
- 2000-Patient study tracks liver shunt outcomes
- 240 cirrhosis patients studied to uncover hidden clot risks
- New combo therapy shows promise for tough-to-treat liver cancer
- Could a blood thinner and heart pill prevent deadly liver complications?